EXoPERT EMERALD Clinical Study
NCT07186296
This study is recruiting at 9 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhanced Raman spectroscopy (SERS) profiles of extracellular vesicles (EVs) extracted from human plasma for the early detection of multiple cancers, including lung, ovarian, breast, pancreatic, and colorectal cancers.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Colon Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Lung Cancer
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- EXoPERT
- Last updated on ClinicalTrials.gov
- July 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Tibor Rubin VA Medical Center · Long Beach, CA
- City of Hope Duarte Cancer Center · Los Angeles, CA
Hawaii · 1
- University of Hawaii Cancer Center · Honolulu, HI
Kentucky · 2
- Lexington VA Healthcare System · Lexington, KY
- KCTL · Louisville, KY
Maryland · 1
- John Hopkins University · Baltimore, MD
New York · 3
- Albany Stratton VA Medical Center · Albany, NY
- Bronx Veterans Medical Research Foundation · The Bronx, NY
- VA Hudson Valley Healthcare System · Wappingers Falls, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.